Roy S. Herbst, MD, PhD | Authors

OGDEN CLINIC

4650 HARRISON BLVD

Articles

Roy S. Herbst, MD, PhD, Discusses ADAURA Trial and Future of Lung Cancer Treatment

June 12, 2020

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed the future of lung cancer treatment to follow the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.

Roy S. Herbst, MD, PhD, Talks Key Takeaway from Phase III ADAURA Trial

June 03, 2020

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.

Future Directions of Monoclonal Antibody Use in Personalized Lung Cancer Therapy

November 30, 2010

With the new direction in research and clinical trials, treating patients who most benefit from treatment with minimal toxicity will continue to be the mainstay of personalized cancer therapy.

Inhalation Therapy for Lung Cancer ‘Primed for Growth,’ Investigator Says

March 01, 2005

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.

Erlotinib Prolongs Survival in Never Smokers, Subgroup Analysis Shows

March 01, 2005

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.

Congress Denies FDA Power to Regulate Tobacco Products

March 01, 2005

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.

Investigators Seek Markers for Sensitivity to EGFR Inhibitors

March 01, 2005

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.